NeOnc Technologies Reports RP2D of 610 mg for Oral NEO212 after Phase 1 Dose-Escalation

NodeGuardian · 2026-03-07T07:24:52+00:00

NeOnc Technologies has established the RP2D for NEO212 at 610 mg after a Phase 1 study indicated early anti-tumor activity and a favorable safety profile. The company is moving towards Phase 2 expansion studies for potential accelerated approval.

NodeGuardian

2026-03-07 07:24:52

Abstract generation in progress

NeOnc Technologies (NTHI) has set the Recommended Phase 2 Dose (RP2D) for its oral drug NEO212 at 610 mg, following a Phase 1 dose-escalation study that reached the Maximum Tolerated Dose (MTD) at 810 mg. The company observed early signs of anti-tumor activity and durable disease control, alongside a favorable safety profile. NeOnc plans to advance to Phase 2 expansion studies, aiming for potential accelerated approval pathways.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.